The best alternative to Mounjaro for weight loss is Zepbound — the exact same molecule (tirzepatide) FDA-approved for weight management. Other options include Wegovy (semaglutide), Contrave, phentermine, and Saxenda.
Why look beyond Mounjaro for weight loss
Mounjaro is FDA-approved for type 2 diabetes, not weight management. Using it off-label means:
- Insurance denial. Without a diabetes diagnosis, most plans won’t cover Mounjaro. That can mean high out-of-pocket cost.
- Billing risk. Off-label prescriptions can be flagged and denied retroactively by insurers.
- Wrong monitoring. Diabetes prescriptions focus on glycemic control, not weight loss outcomes.
The good news: Zepbound contains the identical tirzepatide molecule at the identical doses, but with proper FDA approval for weight loss.
Best alternatives to Mounjaro
1. Zepbound (tirzepatide)
Identical molecule to Mounjaro. Same dual GIP/GLP-1 mechanism. Same 2.5–15 mg dose range. But FDA-approved for chronic weight management and obstructive sleep apnea. This is the most direct “alternative” — it’s Mounjaro’s weight loss twin.
2. Wegovy (semaglutide 2.4 mg)
A GLP-1-only receptor agonist. Produces slightly less weight loss than tirzepatide in trials (~15% vs. ~22.5%) but has FDA-approved cardiovascular benefit (MACE reduction). Strong option if tirzepatide isn’t covered or tolerated.
3. Contrave (naltrexone/bupropion)
Targets the brain’s reward system rather than gut hormones. Oral medication. Best for patients whose weight gain is driven by emotional eating or food cravings. More affordable than GLP-1 medications.
4. Phentermine
Short-term appetite suppressant. Extremely affordable. Useful as a kickstart or bridge therapy while pursuing GLP-1 coverage.
5. Saxenda (liraglutide 3.0 mg)
A daily GLP-1 injection for weight loss. Less effective than Wegovy or Zepbound but available when those aren’t an option.
Quick comparison
| Medication | Class | Avg Weight Loss | Administration | Approx. Cost |
|---|---|---|---|---|
| Zepbound | GIP/GLP-1 | ~22.5% | Weekly injection | Insurance or self-pay |
| Wegovy | GLP-1 | ~15% | Weekly injection | Insurance or self-pay |
| Contrave | Opioid antagonist/NDRI | ~5–6% | Oral, twice daily | Varies by plan/pharmacy |
| Phentermine | Sympathomimetic | 5–7% | Oral, daily | Often low cost |
| Saxenda | GLP-1 | ~8% | Daily injection | Insurance or self-pay |
Important safety information: All GLP-1 and GIP/GLP-1 receptor agonists (Zepbound, Wegovy, Saxenda) carry a boxed warning about thyroid C-cell tumors (medullary thyroid carcinoma) based on animal studies. They are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Discuss your full medical history with your clinician before starting treatment.
How to choose
- Zepbound — identical tirzepatide, proper weight loss approval
- Wegovy — FDA-approved MACE reduction via SELECT trial
- Contrave — targets reward pathways, oral medication
- Phentermine — often low cost, effective short-term
PEAK’s approach
PEAK prescribes Zepbound, Wegovy, Contrave, phentermine, and Saxenda — all FDA-approved for weight loss. We do not prescribe Mounjaro for weight management because Zepbound provides the identical molecule with the correct indication.
Your clinician will evaluate your health profile, insurance coverage, and goals to recommend the best option. Schedule a consultation to get started.
